Non small cell lung cancer overview (David Ross Camidge)
- Watch video(FLV)
This section includes information and resources about Cancer for journalists: Boehringer Ingelheim press releases, background information, related press kits and a collection of images and videos.
Boehringer Ingelheim submits nintedanib*, a novel oncology compound, for European approval- For non U.S. Media Only
Nintedanib* extended survival beyond one year for advanced adenocarcinoma patients after prior first-line chemotherapy- For non U.S. Media Only
GIOTRIF® (afatinib)* approved in Europe for patients with EGFR mutation positive lung cancer
Volasertib* receives FDA Breakthrough Therapy designation for treatment of patients with acute myeloid leukaemia
Afatinib* shows benefits for EGFR mutation positive non-small cell lung cancer patients across various efficacy endpoints